The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...